絞り込み

16545

広告

辺野古承認撤回 県が審査請求弁明書を国交相に送付 (毎日新聞)

[PR] 沖縄県は19日、米軍普天間飛行場(宜野湾市)の名護市辺野古移設を巡り、辺野古沿岸部の埋め立て承認を撤回した県への対抗措置として、政府が行った行政不服審...

  1. 免疫受容体CD300fの機能促進で偽アレ...
  2. 伊勢谷友介と森星のデートをNEWSポスト...
  3. 韓中首脳「朝鮮半島問題、解決の機が熟しつ...
  4. 2025年万博 今週開催地が決定 大阪府...

ニュース一覧

[Anticoagulants: current topics].

著者 Morishita E
Rinsho Ketsueki.2018 ; 59(6):774-783.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (21view , 0users)

Full Text Sources

Despite the introduction of direct oral anticoagulants (DOAC), the need for more effective and safer antithrombotic strategies exists. Recently, the findings stating that the contact system is important for thrombus formation has identified factor XI as a potential target for new anticoagulants. Approximately 20-30% of patients who develop venous thromboembolism (VTE) also have cancer. To date, the drugs primarily used in the treatment of VTE are heparin in the acute phase and warfarin in the chronic phase. Recently, a large-scale international clinical trial, which examined the composite outcomes of VTE recurrence and major bleeding in cancer patients, found that edoxaban, a direct factor Xa inhibitor, is not inferior to low-molecular-weight heparin. The study also showed that DOACs have a promising potential to prove therapeutically effective in future studies. Anticoagulants are associated with a severe side effect, bleeding, which makes emergency neutralization an important concern. Four-factor prothrombin complex concentrate can be used to reverse the effect of warfarin and could also be effective as a neutralizing agent in patients having received DOACs. Moreover, more specific reversing agents include the approved human monoclonal antibody fragment idarucizumab for reversing the effects of dabigatran.
PMID: 29973459 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード